Osimertinib In EGFR Mutant Lung Cancer

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT03586453
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Osimertinib — DRUG
    Patients who fulfill eligibility criteria will be entered into the trial to receive Osimertinib. After the screening procedures confirm participation in the research study: * Osimertinib: Oral, Daily 28 day cycle. * Radiographic assessment: every 2 cycles for first 6 months and then every 3 cycles until disease progression. * Tumor biopsy between C4 and C8 and at disease progression

Study Details

This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: \- Osimertinib (Tagrisso)

Key Dates

Start date
Aug 13, 2018
Status verified
Apr 2026
Primary completion
Feb 28, 2028
Completion
Sep 1, 2028

Study Design

Enrollment
30 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Osimertinib
    Osimertinib: Oral, once a day, dosage determined per protocol

Primary Outcome Measure

Mechanisms of resistance to Osimertinib [ Time Frame: 4 Months ]

Locations (2)

FacilityCityStateZIPSite coordinators
Beth Israel Deaconess Medical CenterBostonMassachusetts02215-
Dana-Farber Cancer InstituteBostonMassachusetts02215-

Find similar trials in Boston, MA

By research site
Beth Israel Deaconess Medical Center· Boston, MADana-Farber Cancer Institute· Boston, MA

Related Studies